Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming het aandeel van 2017

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,712   -0,015   (-2,00%) Dagrange 0,709 - 0,724 2.262.957   Gem. (3M) 4,8M

Pharming het aandeel van 2017

Volgen
50.750 Posts
Pagina: «« 1 ... 2336 2337 2338 2339 2340 ... 2538 »» | Laatste | Omlaag ↓
  2. [verwijderd] 26 oktober 2017 06:35
    Wat leesvoer om de tijd te verkorten:

    Pharming Group NV (:PHGUF): Wall Street Analyst Opinions in Focus

    October 25, 2017 Kenneth Searles


    Analysts often provide buy/sell/hold recommendations for companies that they cover. Investors have the ability to follow these sell-side ratings in order to assist with stock analysis. Wall Street analyst ratings may have various interpretations. According to analysts taken into consideration by Zacks Research, the current average broker recommendation on shares of Pharming Group NV (:PHGUF) is currently 1. This rating lands on a scale between 1 and 5. Following this scale, a rating of 1 would indicate a Strong Buy, and a rating of 5 would indicate a Strong Sell recommendation. Out of all the analysts providing ratings, 3 have rated the stock a Strong Buy or Buy, according to Zacks Research.

    Traders may be going deeper into the playbook in order to scoop up profits in the current stock market environment. The first half of the year has produced plenty of big winners. Investors will be closely monitoring the most recent earnings releases to hopefully spot the next big mover. Traders may be looking to more closely define some major trends in order to identify which way the momentum is going to carry the stock market into the close of the calendar year. Keeping track of all the financial news and global happenings can be a tall order, even for the most seasoned investors. Staying the course while following a sound investing plan can help the individual investor become prepared for whatever lies ahead. The optimists still believe there is much more room for growth in the markets while the pessimists are calling for a major reversal in the near future. Traders and investors will be closely tracking the major economic news to help come to a solid conclusion about which way the markets are headed. Staying up on the fundamentals as well as the popular technical indicators may help the investor sort through the maze and prepare for the next stage.

    Taking a quick look at the current quarter EPS consensus estimate for Pharming Group NV (:PHGUF), we can see that the most recent level is sitting at -0.01. This EPS projection uses 2 Sell-Side analysts polled by Zacks Research. For the previous reported quarter, the company posted a quarterly EPS of 20170601. Covering analysts have the tough job of following companies and offering future estimates. These estimates are often closely followed on the Street, and earnings beats or misses revolve around these projections. Sometimes these predictions are extremely close to the actual reported number, and other times they may be way off. When a company posts actual earnings numbers, the surprise factor can lead to sudden stock price fluctuations. If a company meets and beats estimates and posts a positive earnings surprise, the stock may see a near-term bump. On the other end, a negative surprise may send the stock in the opposite direction. Many investors will choose to trade with caution around earnings releases and wait to make a move until after the major activity has subsided.

    Zooming in on recent stock price action for Pharming Group NV (:PHGUF), we note that shares are trading near the 0.88 level. Investors will often follow stock price levels in relation to the 52-week high and low levels. The 52-week high is presently 0.98, and the 52-week low is sitting at 0.22. When a stock price is getting close to either the 52-week high or 52-week low, investors may track activity to watch for a move past the established mark. Over the last 12 weeks, shares have seen a change of 74.26%. Heading further back to the start of the year, we note that shares have seen a change of 252%. Focusing in closer to the last 4 weeks, shares have seen a change of 7.32%. Over the past five trading days, the stock has changed -4.35%.

    Sell-side Wall Street analysts will commonly offer stock price target estimates. Many investors pay close attention to where the analysts project the stock moving in the future. After a recent scan, we can see that analysts polled by Zacks Research have set a consensus price target of $-200 on shares of Pharming Group NV (:PHGUF). Price target estimates can be calculated using various methods, and they may be quite different depending on the individual analyst. A fully researched analyst report will generally provide detailed reasoning for a specific target price prediction. Some investors may track analyst targets very closely and use the information to complement their own stock research.
  11. jurpsy 26 oktober 2017 07:00
    Sijmen de Vries, Chief Executive Officer, commented:
    “These are excellent quarterly results and show that we are on the right track with our strategy for
    RUCONEST® in all markets. We now see real growth in terms of both volume and value for
    RUCONEST®. In addition, we continue to make good progress with our pipeline research and
    development programs.
    Towards the end of the quarter we were informed of acute shortages of HAE medication as a result of
    manufacturing issues for certain competitor HAE products, mainly in the US. To help resolve this
    situation for patients, we immediately offered instant access to our patient care programme,
    RUCONEST® SOLUTIONS, including its free starter medication and bridging support for those patients
    in acute need of alternative medication to treat their HAE attacks. We have therefore been supplying
    considerable amounts of RUCONEST® free-of-charge to cover treatment of attacks for the period
    during which those patients are being cleared for RUCONEST® reimbursement. Patients are at the very
    centre of Pharming’s business and we are doing our best to ensure that HAE patients get effective
    treatment. As a result of this situation, we have accelerated planned increases in capacity across our
    supply chain. We do not believe this situation has had any real effect on our results for the third
    quarter, but it is likely to have a positive effect on the company’s performance in the fourth quarter.”
  13. [verwijderd] 26 oktober 2017 07:01
    Leiden, The Netherlands, 26 October 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM), the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, presents its (unaudited) financial report for the first nine months and the third quarter ended 30 September 2017.

    Financial highlights

    Revenues for the nine months to 30 September increased to €56.7 million (2016 €8.7 million), with Q3 alone €25.9 million ($30.5 million, up 73% on Q2 2017), due to strong growth in US and EU sales
    Q3 operating profit up to €8.5 million compared with a loss of €3.2 million in Q3 2016
    Q3 net result improved to €7.5 million loss compared with a loss of €24.5 million in Q2
    Positive cashflows during Q3 increased the cash position to €38.6 million from €25.2 million at June 30 2017 (and €17.0 million at 30 September 2016)

    Operational highlights during the third quarter

    On September 11, following the conclusion of the End-of-Phase 2 interactions with the US Food and Drug Administration (FDA), Pharming announced that it will submit a supplemental Biologics License Application (sBLA) to the FDA for review in Q4 of this year for prophylaxis of angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE) as an expanded indication for RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa]
    On September 26, the Company, in association with HAEi (the international umbrella organization for the world’s HAE patient groups), announced the appointment of Inceptua Medicines Access as their new distribution partner for the “HAEi Global Access Program” (HAEi GAP) enabling patients in all countries where Pharming’s product RUCONEST® is not commercially available to gain access to the drug through an ethical and regulatory-compliant mechanism
    Positive results were obtained from a Phase II clinical trial investigating the use of RUCONEST® for the treatment of HAE attacks in children

    Post period highlights

    The RUCONEST® US Biologics License Application has been transferred from Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX) to Pharming, following the acquisition of the North American commercial rights to the product in December 2016


    Sijmen de Vries, Chief Executive Officer, commented:

    “These are excellent quarterly results and show that we are on the right track with our strategy for RUCONEST® in all markets. We now see real growth in terms of both volume and value for RUCONEST®. In addition, we continue to make good progress with our pipeline research and development programs.

    Towards the end of the quarter we were informed of acute shortages of HAE medication as a result of manufacturing issues for certain competitor HAE products, mainly in the US. To help resolve this situation for patients, we immediately offered instant access to our patient care programme, RUCONEST® SOLUTIONS, including its free starter medication and bridging support for those patients in acute need of alternative medication to treat their HAE attacks. We have therefore been supplying considerable amounts of RUCONEST® free-of-charge to cover treatment of attacks for the period during which those patients are being cleared for RUCONEST® reimbursement. Patients are at the very centre of Pharming’s business and we are doing our best to ensure that HAE patients get effective treatment. As a result of this situation, we have accelerated planned increases in capacity across our supply chain. We do not believe this situation has had any real effect on our results for the third quarter, but it is likely to have a positive effect on the company’s performance in the fourth quarter.”
  15. jurpsy 26 oktober 2017 07:02
    Outlook
    For the remainder of 2017, the Company expects:
    • FY 2017 revenues from product sales to exceed analysts’ forecasts and for the fourth
    quarter results to exceed the third quarter significantly, driven by underlying increasing
    demand
    • Achievement of continued operating profit and positive cashflows for the remaining quarter
    • Continued investment in the production of RUCONEST® in order to ensure continuity of
    supply to the growing markets in the US, Europe and the RoW
    • Investment in the approval for RUCONEST® in prophylaxis of HAE and in further clinical trial
    development of a small, fast IV version and new intramuscular, subcutaneous and other
    delivery options for RUCONEST®
    • Continued and enhanced support for patients in all territories, as we continue to believe
    that RUCONEST® represents a fast, effective, reliable and safe therapy option available to
    HAE patients
    • Continued progress in the new pipeline programs in Pompe disease and Fabry’s disease, and
    additional development opportunities and assets as they occur
  16. [verwijderd] 26 oktober 2017 07:02
    Sijmen de Vries, Chief Executive Officer, commented:

    “These are excellent quarterly results and show that we are on the right track with our strategy for RUCONEST® in all markets. We now see real growth in terms of both volume and value for RUCONEST®. In addition, we continue to make good progress with our pipeline research and development programs.

    Towards the end of the quarter we were informed of acute shortages of HAE medication as a result of manufacturing issues for certain competitor HAE products, mainly in the US. To help resolve this situation for patients, we immediately offered instant access to our patient care programme, RUCONEST® SOLUTIONS, including its free starter medication and bridging support for those patients in acute need of alternative medication to treat their HAE attacks. We have therefore been supplying considerable amounts of RUCONEST® free-of-charge to cover treatment of attacks for the period during which those patients are being cleared for RUCONEST® reimbursement. Patients are at the very centre of Pharming’s business and we are doing our best to ensure that HAE patients get effective treatment. As a result of this situation, we have accelerated planned increases in capacity across our supply chain. We do not believe this situation has had any real effect on our results for the third quarter, but it is likely to have a positive effect on the company’s performance in the fourth quarter.”

    "Dit zijn uitstekende kwartaalresultaten en laten zien dat we op de goede weg zijn met onze strategie voor RUCONEST® op alle markten. We zien nu reële groei in termen van volume en waarde voor RUCONEST®. Daarnaast blijven we goede vooruitgang met onze pijpleidings onderzoeks- en ontwikkelingsprogramma's.

    Tegen het einde van het kwartaal werden we op de hoogte gesteld van acute tekorten aan HAE medicatie als gevolg van fabricageproblemen voor bepaalde concurrent HAE producten, voornamelijk in de VS. Om deze situatie voor patiënten op te lossen, bieden we direct toegang tot ons patiëntenzorgprogramma, RUCONEST® SOLUTIONS, met inbegrip van de gratis voorgangsmedicatie en overbruggingsondersteuning voor die patiënten in acute behoefte aan alternatieve geneesmiddelen om hun HAE-aanvallen te behandelen. Daarom hebben we aanzienlijke hoeveelheden RUCONEST® gratis geleverd ter dekking van de behandeling van aanvallen voor de periode waarin die patiënten worden opgeheven voor RUCONEST®-vergoeding. Patiënten staan ??centraal in de activiteiten van Pharming en wij doen ons best om ervoor te zorgen dat HAE-patiënten efficiënte behandeling krijgen. Als gevolg van deze situatie hebben we geplande capaciteitsverhogingen in onze leveranciersketen versneld. Wij geloven niet dat deze situatie voor het derde kwartaal echt effect heeft op onze resultaten, maar het zal waarschijnlijk een positief effect hebben op de prestaties van het bedrijf in het vierde kwartaal. "

50.750 Posts
Pagina: «« 1 ... 2336 2337 2338 2339 2340 ... 2538 »» | Laatste |Omhoog ↑

Direct naar Forum

Premium

Vertrek CEO overschaduwt goede resultaten Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: volop groeimotoren voor Pharming
  2. AEX opent waarschijnlijk hóger op Super Thursday met Besi, Unilever en Pharming
  3. Topman De Vries stopt bij Pharming
  4. Pharming start met Fase II klinische studie leniolisib
  5. Pharming: herstelpotentieel van 100%
  6. Slotcall: BAM en Pharming vinden gretig aftrek op groen gekleurd Damrak
  7. Micron-effect op de beurs? AEX gaat fraaie opening tegemoet, chipaandelen Azië vliegen
  8. Brits groen licht voor Joenja van Pharming
  9. Video: CEO tevreden over ontwikkelingen bij Pharming
  10. Dubbeltje op zijn kant voor AEX, terwijl cijferstorm aantrekt tot windkracht 10